Palavras-chave
HIV
fosfolipase
proteinase
cavidade bucal
Como Citar
Resumo
A produção de proteinase e fosfolipase é considerada como um dos principais mecanismos de patogenicidade de C. albicans, pois essas enzimas são importantes na invasão tecidual. Este estudo avaliou a produção dessas exoenzimas de 50 isolados bucais de C. albicans de pacientes HIV positivos (HIV+), sob tratamento com terapia antirretroviral altamente ativo (HAART), e dos isolados de 50 indivíduos controle. Para os testes de fosfolipase e proteinase, foram empregados meios de cultura contendo, respectivamente, gema de ovo e albumina bovina. Os resultados foram obtidos pela medida do diâmetro da colônia dividida pela somatória do diâmetro da colônia e do halo de precipitação, definido como Pz. Os dados foram analisados pelo teste t de Student. Houve diferença estatisticamente significante (p = 0001) entre os valores médios de Pz para a proteinase obtida do grupo HIV+ (Pz = 0,358±0,295) e controle (Pz = 0,660±0,370). O mesmo foi observado para a produção de fosfolipase (Pz = 0,399±0,227 grupo HIV+; Pz = 0,635±0,292 controle). Os isolados de C. albicans provenientes dos pacientes HIV+ apresentaram maior produção de fosfolipase e proteinase em relação ao controle, o que indicou que a terapia HAART não reduziu a secreção dessas enzimas pelos isolados dos pacientes HIV+.
Referências
1. Ellepola ANB, Samaranayake LP. Oral candidal infections and antimycotics. Crit Rev Oral Biol Med. 2000;11(2):172-98.
2. Boriollo MF, Rosa EA, Bernardo WL, Gonçalves RB, Höfling JF. Electrophoretic protein patterns and numeical analysis of Candida albicans from the oral cavities of healthy children. Rev Inst Med Trop São Paulo. 2003;45(5):249-7.
3. Sánchez-Vargas LO, Ortiz-López NG, Villar M, Moragues MD, Aguirre JM, Cashat-Cruz M, et al. Point prevalence, microbiology and antifungal susceptibility patterns of oral Candida isolates colonizing or infecting Mexican HIV/AIDS patients and healthy persons. Rev Iberoam Micol. 2005;22(2):83-92.
4. Samaranayake LP, Fidel PL, Naglik JR, Sweet SP, Teanpaisan R, Coogan MM et al. Fungal infections associated with HIV infection. Oral Dis. 2002;8(2):151-60.
5. Bramono K, Yamazaki M, Tsuboi R, Ogawa H. Comparison of proteinase, lipase and alpha-glucosidade activities from the clinical isolates of Candida species. Jpn J Infect Dis. 2006; 9:73-6.
6. Lin AL, Johnson DA, Patterson TF, Wu Y, Lu DL, Shi Q et al. Salivary anticandidal activity and saliva composition in an HIV-infected cohort. Oral Microbiol Immunol. 2001;16 (5):270-8.
7. Nittayananta W, Jealae S, Winn T. Oral Candida in HIV-infected heterosexuals and intravenous drug users in Thailand. J Oral Pathol Med. 2001;30(6):347-54.
8. Al-Abeid HM, Abu-Elteen KH, Elkarmi AZ, Hamad MA. Isolation and characterization of Candida spp. in Jordanian cancer patients: prevalence, pathogenic determinants, and antifungal sensitivity. Jpn J Infect Dis. 2004;57(6):279-84.
9. Hube B, Nagliak J. Candidaalbicans proteinases: resolving the mystery of a gene family. Microbiol. 2001;147:1997-2005.
10. Naglik JR, Challacombe SJ, Hube B. Candidaalbicans secreted aspartly proteinases in virulence and pathogenesis. Microbiol Molec Biol Rev. 2003;67(3):400-28.
11. Naglik JR, Albrecht A, Bader O, Hube B. Candidaalbicans proteinases and host/pathogen interactions. Cell Microbiol. 2004;6(10):915-26.
12. Schaller M, Borelli C, Korting HC, Hube B. Hydrolytic enzymes as virulence factors of Candidaalbicans. Mycoses. 2005;48(6):365-77.
13. Yang YL. Virulence factors of Candida species. J Microbiol Immunol Infect. 2003;36(4):223-38.
14. Ghannoum MA. Potential role of phospholipases in virulence and fungal pathogenesis. Clin Microbiol Rev. 2001;3(1):122-43.
15. Niewerth M, Korting HC. Phospholipases of Candidaalbicans. Mycoses. 2001;44(9):361-7.
16. Gonçalves L de S, Ferreira SM, Silva A Jr, Villoria GE, Costinha LH, Colombo AP. Association of T CD4 lymphocyte levels and chronic periodontitis in HIV-infected brazilian patients undergoing highly active anti-retroviral therapy: clinical results. J Periodontol. 2005;76(6):915-22.
17. Bosco VP, Birman EG, Cury AE, Paula CR. Yeast from the oral cavity of children with AIDS: exoenzyme production and antifungal resistance. Pesq Odont Bras. 2003;17(3):217-22.
18. Back-Brito GN, Mota AJ, Vasconcellos TC, Querido SMR, Jorge AOC. Frequency of Candida spp. in the oral cavity of Brazilian HIV-positive patients and correlation with CD4 cell counts and viral load. Mycopathol. 2009;167(2):81-7.
19. Sandvén P. Laboratory identification and sensitivity testing of yeast isolates. Acta Odonto Scand. 1990;48:27-36.
20. Williams DW, Lewis MAO. Isolation and identification of Candida from the oral cavity. Oral Dis. 2000;6:3-11.
21. Donnely SM, Sullivan DJ, Shanley DB, Coleman DC. Phylogenetic analysis and rapid identification of Candidadubliniensis based on analysis of ACT1 intron and exon sequences. Microbiol. 1999;145:1871-82.
22. Mähnss B, Stehr F, Schäfer W, Neuber K. Comparison of standard phenotypic assays with a PCR method to discriminate Candidaalbicans and Candida dubliniensis. Mycoses. 2005;46: 55-61.
23. Price MF, Wilkinson ID, Gentry LO. Plate method for detection of phospholipase activity in Candidaalbicans. Sabouraudia. 1982;20(1):7-14.
24. Ruchel R, Tegeler R, TROST M. A comparison of secretory proteinases from different strains of Candidaalbicans. Sabouraudia. 1982;20:233-44.
25. Haynes K. Virulence in Candida species. TRENDS Microbiol. 2001; 9(12):591-6.
26. Koga-Ito CY, Lyon JP, Vidotto V, de Resende MA. Virulence factors and antifungal susceptibility of Candidaalbicans isolates from oral candidosis patients and control individuals. Mycopathol. 2006;161(4):219-23.
27. Kantarcioglu AS, Yücel A. Phospholipase and protease activities in clinical Candida isolates with reference to the sources of strains. Mycoses. 2002;45(5-6):160-5.
28. Ribeiro EL, Scroferneker ML, Cavalhaes MS, Campos CC, Nagato GM, Souza NA et al. Phenotypic aspects of oral strains of Candidaalbicans in children with down’s syndrome. Braz J Biol. 2006;66(3):939-44.
29. Candido RC, Azevedo RVP, Komesu MC. Enzimotipagem de espécies de Candida isoladas da cavidade bucal. Rev Bras Med Trop. 2005;33:456-63.
30. Munro CA, Hube B. Anti-fungal therapy at the HAART of viral therapy. Trends Microbiol. 2002;10(4):173-7.
31. Tappuni AR, Fleming GJP. The effect of antiretroviral therapy on the prevalence of oral manifestations in HIV-infected patients: a UK study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2001;92(6):623-8.
32. Ribeiro MA, Miranda AE, Gambale W, Paula CR. Prevalence and exoenzyme secretion by Candidaalbicans isolates from oral and vaginal mucosas of HIV-infected women. Mycopathol. 2004;157(3):255-61.
33. Ryder MI. An update on HIV and periodontal disease. J Periodontol. 2002;73(9):1071-8.
34. Perezous LF, Flaitz CM, Goldschmidt ME, Engelmeier RL. Colonization of Candida species in denture wearers with emphasis on HIV infection: a literatura review. J Prosthet Dent. 2005;93(3):288-93.
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.
Copyright (c) 2011 Graziella Nuernberg Back-Brito, Vivian Narana Ribeiro El Achkar, Aline Lopes Garbim, Rogério de Lima Romeiro, Antonio Olavo Cardoso Jorge, Ivan Balducci, Cristiane Yumi Koga-Ito